- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Ophthalmogenetic testing available from Asper Ophthalmics
Asper Ophthalmics continues to work on the development of new genetic tests for numerous ophthalmologic diseases. Among these are ABCR genetic testing, Usher syndrome testing, Leber congenital amaurosis (LCA) genetic testing, autosomal recessive retinitis pigmentosa (AR-RP) genetic testing, autosomal dominant retinitis pigmentosa (AD-RP) genetic testing, and Bardet Biedl syndrome (BBS) genetic testing.
Asper Ophthalmics continues to work on the development of new genetic tests for numerous ophthalmologic diseases.
Among these are ABCR genetic testing, Usher syndrome testing, Leber congenital amaurosis (LCA) genetic testing, autosomal recessive retinitis pigmentosa (AR-RP) genetic testing, autosomal dominant retinitis pigmentosa (AD-RP) genetic testing, and Bardet Biedl syndrome (BBS) genetic testing.
In addition, the company said it has plans to introduce several new tests this year and update existing tests. New tests will be launched for screening of genetic variations related to Best's disease and congenital stationary night blindness. Both tests will cover approximately 100 mutations. Other testing will be available soon for X-linked retinitis pigmentosa, autosomal dominant optic atrophy, and corneal diseases.
For more information, visit Asper Ophthalmics at Booth 800.
